Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders - PubMed (original) (raw)
Multicenter Study
. 2001 Feb 1;19(3):772-8.
doi: 10.1200/JCO.2001.19.3.772.
N Dhedin, M F Mamzer Bruneel, S Choquet, O Hermine, R Porcher, S Nguyen Quoc, F Davi, F Charlotte, R Dorent, B Barrou, J P Vernant, M Raphael, V Levy
Affiliations
- PMID: 11157030
- DOI: 10.1200/JCO.2001.19.3.772
Multicenter Study
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
V Leblond et al. J Clin Oncol. 2001.
Abstract
Purpose: Prognostic studies of posttransplantation lymphoproliferative disorders (PTLDs) are hindered by the small number of cases at each transplant center. We analyzed prognostic factors and long-term outcome according to clinical manifestations, pathologic features, and treatment and investigated the prognostic value of the non-Hodgkin's lymphoma International Prognostic Index (IPI) in 61 patients with PTLD.
Patients and methods: We studied 61 patients in two institutions who developed PTLD and analyzed factors influencing the complete remission and survival rates.
Results: In univariate analysis, factors predictive of failure to achieve complete remission were performance status (PS) > or = (P =.0001) and nondetection of Epstein-Barr virus (EBV) in the tumor (P =.01). Only a negative link with PS > or = 2 was observed in multivariate analysis. In univariate analysis, factors predictive of lower survival were PS > or = 2, the number of sites (one v > one), primary CNS localization, T-cell origin, monoclonality, nondetection of EBV, and treatment with chemotherapy. The IPI failed to identify a patient subgroup with better survival and was less predictive of the response rate than was a specific index using two risk factors (PS and number of involved sites), which defined three groups of patients: low-risk patients whose median survival time has not yet been reached, intermediate-risk patients with a median survival time of 34 months, and high-risk patients with a median survival time of 1 month.
Conclusion: PS and the number of involved sites defined three risk groups in our population. The value of these prognostic factors needs to be confirmed in larger cohorts of patients treated in prospective multicenter studies.
Similar articles
- Identification of prognostic factors in post-transplant lymphoproliferative disorders.
Choquet S, Mamzer BM, Hermine O, Porcher R, Nguyen QS, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V, Leblond V. Choquet S, et al. Recent Results Cancer Res. 2002;159:67-80. doi: 10.1007/978-3-642-56352-2_9. Recent Results Cancer Res. 2002. PMID: 11785846 - Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs. Muti G, et al. Haematologica. 2002 Jan;87(1):67-77. Haematologica. 2002. PMID: 11801467 - Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Knight JS, et al. J Clin Oncol. 2009 Jul 10;27(20):3354-62. doi: 10.1200/JCO.2008.20.0857. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451438 - New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
Preiksaitis JK. Preiksaitis JK. Clin Infect Dis. 2004 Oct 1;39(7):1016-23. doi: 10.1086/424447. Epub 2004 Sep 13. Clin Infect Dis. 2004. PMID: 15472855 Review. - [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J. Franco A, et al. Nefrologia. 2002;22(5):463-9. Nefrologia. 2002. PMID: 12497748 Review. Spanish.
Cited by
- Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria.
King RL, Khurana A, Mwangi R, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Kushwaha SS, Cerhan JR, Habermann TM. King RL, et al. Hemasphere. 2021 Sep 6;5(10):e640. doi: 10.1097/HS9.0000000000000640. eCollection 2021 Oct. Hemasphere. 2021. PMID: 34514344 Free PMC article. - Post-Transplant Lymphoproliferative Disorders.
Dharnidharka VR, Ruzinova MB, Marks LJ. Dharnidharka VR, et al. Semin Nephrol. 2024 Jan;44(1):151503. doi: 10.1016/j.semnephrol.2024.151503. Epub 2024 Mar 22. Semin Nephrol. 2024. PMID: 38519279 Free PMC article. Review. - Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.
Faye A, Vilmer E. Faye A, et al. Paediatr Drugs. 2005;7(1):55-65. doi: 10.2165/00148581-200507010-00005. Paediatr Drugs. 2005. PMID: 15777111 Review. - Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.
Franceschi S, Polesel J, Rickenbach M, Dal Maso L, Probst-Hensch NM, Fux C, Cavassini M, Hasse B, Kofler A, Ledergerber B, Erb P, Clifford GM. Franceschi S, et al. Br J Cancer. 2006 Dec 4;95(11):1598-602. doi: 10.1038/sj.bjc.6603472. Epub 2006 Nov 14. Br J Cancer. 2006. PMID: 17106439 Free PMC article. - Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong.
Cheung CY, Ma MKM, Chau KF, Chak WL, Tang SCW. Cheung CY, et al. Oncotarget. 2017 Jun 30;8(57):96903-96912. doi: 10.18632/oncotarget.18890. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228580 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical